Clinical trials: Quitting Smoking
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Smoking Cessation
Cumulative Skin Irritation Potential of a New 15 mg Nicotine Patch
An investigation on the cumulative skin irritation potential of a newly developed 15 mg nicotine patch. Evaluation of skin irritation of a newly developed 15 mg nicotine transdermal patch.
- Trial name
- NCT00965913
- Testing
- Nicotine Patch, Nicotine Patch Comparator
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- McNeil AB
Smoking, Abdominal Aortic Aneurysm
Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.
The purpose of this study was to evaluate the reduction of the Abdominal Aortic Aneurysm (AAA) annual growth rate in patients who switched from smoking cigarettes to using IQOS as compared to patients who continued to smoke…
- Conditions
- Smoking, Abdominal Aortic Aneurysm, IQOS Use
- Trial name
- NCT03837704
- Testing
- IQOS, Cigarette, Smoking Cessation
- Where
- 13 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Philip Morris Products S.A.
Smokers
Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.
This study is designed to determine the efficacy of high nicotine-specific antibody titers in smoking cessation.
- Trial name
- NCT00736047
- Testing
- NIC002
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Novartis
Smoking Cessation
Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE)
Surinabant is a new, potent and selective antagonist for the cannabinoid CB1 receptor, which might be clinically useful in the treatment of dependence to nicotine.
- Trial name
- NCT00432575
- Testing
- surinabant (SR147778)
- Where
- 8 sites in Belgium, France and 6 more
- Volunteers
- 810 people
- Sponsor
- Sanofi
Tobacco Dependence
Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum
Bioequivalence between oral nicotine replacement products and Nicorette® gum.
- Trial name
- NCT01113424
- Testing
- Nicotine, Nicorette® (Nicotine Gum)
- Where
- Sweden
- Volunteers
- 88 people
- Sponsor
- McNeil AB
Smoking Cessation
Nalmefene Smoking Cessation Study
To determine if nalmefene is safe and effective in smoking cessation.
- Trial name
- NCT00202696
- Testing
- nalmefene
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Somaxon Pharmaceuticals
Smoking Cessation, Nicotine Addiction
Innovative Digital Therapeutic for Smoking Cessation
This study is comparing the efficacy of two smoking cessation apps.
- Conditions
- Smoking Cessation, Nicotine Addiction, Drug Addiction, Drug Dependence
- Trial name
- NCT03694327
- Testing
- CT-101-M, QuitGuide
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- My Digital Study
Smoking Cessation
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.
- Trial name
- NCT00282984
- Testing
- Varenicline
- Where
- 39 sites in United States, Argentina and 13 more
- Volunteers
- 714 people
- Sponsor
- Pfizer
Smoking Cessation, Harm Reduction
Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders
To determine whether smokers who initially respond (within 2 weeks) to nicotine products (including nicotine replacement therapy, e-cigarettes, nicotine pouches) by reducing their smoking by ≥50% can be successfully maintained on…
- Trial name
- NCT06554873
- Testing
- Nicoderm, Nicorette 4Mg Chewing Gum, Nicorette Lozenge Product
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation, Tobacco Use Cessation
Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals
Nicotine is highly addictive and many individuals are unable to quit smoking even with treatment. The purpose of this study is to determine the effectiveness of various doses of NicVAX in treating nicotine dependent individuals.
- Trial name
- NCT00218413
- Testing
- NicVAX
- Where
- Netherlands
- Volunteers
- 51 people
- Sponsor
- Nabi Biopharmaceuticals
Smoking Cessation
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation.
- Trial name
- NCT00150254
- Testing
- CP-526,555 (varenicline)
- Where
- 13 sites in United States
- Volunteers
- 625 people
- Sponsor
- Pfizer
Smoking
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit.
- Trial name
- RENEW-Smk-1 (NCT07223840)
- Testing
- Brenipatide
- Where
- 29 sites in United States, China and 1 more
- Volunteers
- 222 people
- Sponsor
- Eli Lilly and Company
Tobacco Dependence
Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum
Single-dose pharmacokinetics with two new oral nicotine replacement products and Nicorette® gum.
- Trial name
- NCT01152723
- Testing
- Nicotine
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- McNeil AB
Malformations
Varenicline Pregnancy Cohort Study
A prospective population-based cohort study to examine whether varenicline use during pregnancy is associated with an increased risk of major congenital malformations in infants above that associated with smoking during pregnancy.
- Trial name
- NCT01290445
- Testing
- varenicline, cigarette smoke from maternal smoking, Non-Exposure
- Volunteers
- 885,185 people
- Sponsor
- Pfizer
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc
Depressive Disorder, Pregnancy
Bupropion and Specific Cardiovascular Malformations
The study is an extension of earlier work based on a retrospective epidemiologic study of infants born to women who were exposed to bupropion in their estimated first trimester of pregnancy using data from a large US health plan…
- Conditions
- Depressive Disorder, Pregnancy, Smoking Cessation
- Trial name
- NCT01165255
- Testing
- 3. Exposure to other antidepressants during the first trimester comparison cohort, 2. Exposure to bupropion outside the first trimester comparison cohort, 1. Exposure to bupropion during the first trimester
- Volunteers
- 7,005 people
- Sponsor
- GlaxoSmithKline
Smoking Cessation
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg medication for 12 weeks in smokers
- Trial name
- NCT00483002
- Testing
- varenicline
- Volunteers
- 3,719 people
- Sponsor
- Pfizer
Smoking Cessation, Pharmacokinetics
A Clinical Trial to Compare Pharmacokinetics of the "CDFF0318" and "Champix Tab. 1mg"
A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics after Administration of the "CDFF0318" and "Champix Tab. 1mg (Varenicline tartrate)" in Healthy Male Volunteers
- Trial name
- NCT04631874
- Testing
- CDFF0318, Champix
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- CTC Bio, Inc.
Smoking Cessation
Single-Dose Bioequivalence Study Comparing Two 2 mg Nicotine Lozenges
The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess bioequivalence between a new nicotine lozenge and a reference nicotine lozenge in healthy smokers.
- Trial name
- NCT03432273
- Testing
- Nicotine lozenge
- Where
- South Africa
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Fertin Pharma A/S